New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
06:31 EDTARIAFoundation Medicine, ARIAD announce collaboration to study AP26113
Foundation Medicine and ARIAD announced a genomic profiling collaboration to study AP26113, ARIAD's investigational dual-inhibitor of ALK and EGFR in patients with non-small cell lung cancer and other cancers. Foundation Medicine will work with ARIAD to generate genomic profile information for patients enrolled in ARIAD's ongoing Phase 1/2 trial and these data will be matched with clinical observations to understand the activity and selectivity profile of AP26113.
News For ARIA From The Last 14 Days
Check below for free stories on ARIA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 7, 2014
10:07 EDTARIAARIAD has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov will host a conference call with CEO Harvey Berger on April 10 at 10 am.
April 2, 2014
07:35 EDTARIAARIAD appoints Hugh Cole as Chief Business Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use